Ascendis plans to meet with FDA in request to approve TransCon PTH
Ascendis Pharma will request to meet with the U.S. Food and Drug Administration (FDA) in an effort to gain approval of TransCon PTH, its experimental hormone replacement therapy for hypoparathyroidism. “Based on our clinical experience with TransCon PTH to date, we have seen the improvement in the…